Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Adalimumab.

1 Changing Pattern in the Prescription of Biological Treatment in Rheumatoid Arthritis. A 7- year Follow-up of 1839 Patients in Southern Sweden.

Maria K. Söderlin
Pierre Geborek
Maria K. Söderlin

August 2016

Objective. To study prescription patterns of biological treatment in rheumatoid arthritis (RA) patie...

Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort.

Chevreul, Karine
Haour, Georges
Lucier, Sandy
Harvard, Stephanie
Laroche, Marie-Laure
Mariette, Xavier
Saraux, Alain
Durand-Zaleski, Isabelle
Guillemin, Francis
Fautrel, Bruno

January 2014

International audienceOBJECTIVES: To estimate annual direct costs of early RA by resource component ...

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis : An evaluation of costs and effects

Krieckaert, C. L M
Nair, S. C.
Nurmohamed, M. T.
Van Dongen, C. J J
Lems, W. F.
Lafeber, F. P J G
Bijlsma, J. W J
Koffijberg, H.
Wolbink, G.
Welsing, P. M J

February 2015

Objective: To evaluate the cost-effectiveness of personalised treatment for rheumatoid arthritis (RA...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Etanercept.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of second-line biologic agent-Rituximab.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.

Griffiths, RI
Bar-Din, M
MacLean, CH
Sullivan, EM
Herbert, RJ
Yelin, EH

August 2000

OBJECTIVE: To identify costs among rheumatoid arthritis (RA) patients receiving alternative disease-...

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.

Griffiths, RI
Bar-Din, M
MacLean, C
Sullivan, EM
Herbert, RJ
Yelin, EH

April 2001

We compared medical resource use and costs among rheumatoid arthritis (RA) patients receiving altern...

Economic consequences and potential benefits

Fautrel, Bruno
Verstappen, Suzanne M. M.
Boonen, Annelies

August 2011

Patients with established rheumatoid arthritis (RA) may incur important resource utilisation and wor...

Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis

Hyoungyoung Kim
Soo-Kyung Cho
Seongmi Choi
Seul Gi Im
Sun-Young Jung
Eun Jin Jang
Yoon-Kyoung Sung

June 2021

Objectives: To compare healthcare utilization and medical costs between patients with seronegative (...

Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada

Weijers L.
Baerwald C.
Mennini F. S.
Rodriguez-Heredia J. M.
Bergman M. J.
Choquette D.
Herrmann K. H.
Attina G.
Nappi C.
Merino S. J.
Patel C.
Mtibaa M.
Foo J.

January 2017

Rheumatoid arthritis (RA) is a chronic inflammatory disorder leading to disability and reduced quali...

Costs of treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs in rheumatic diseases – data from the Romanian Registry of Rheumatic Diseases

Catalin Codreanu
Claudiu C. Popescu
Bogdan Baleanu
Corina Mogosan

March 2020

Given the limited resources of the health system, rheumatologists are interested in reducing the cos...

Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis

Sangiorgi D
Benucci M
Nappi C
Perrone V
Buda S
Degli Esposti L

November 2015

Diego Sangiorgi,1 Maurizio Benucci,2 Carmela Nappi,3 Valentina Perrone,1 Stefano Buda,1 Luca Degli E...

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

Krieckaert, C.L.M.
Nair, S.C.
Nurmohamed, M.T.
Dongen, C.J.J. van
Lems, W.F.
Lafeber, F.P.J.G.
Bijlsma, J.W.J.
Koffijberg, H.
Wolbink, G.
Welsing, P.M.J.

January 2015

Objective To evaluate the cost-effectiveness of personalised treatment for rheumatoid arthritis (RA)...

Lapadula, G
Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428)

January 2012

Rheumatoid arthritis (RA) societal costs are high because the disease may cause not only restricted ...

1 Changing Pattern in the Prescription of Biological Treatment in Rheumatoid Arthritis. A 7- year Follow-up of 1839 Patients in Southern Sweden.

Maria K. Söderlin
Pierre Geborek
Maria K. Söderlin

August 2016

Objective. To study prescription patterns of biological treatment in rheumatoid arthritis (RA) patie...

Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort.

Chevreul, Karine
Haour, Georges
Lucier, Sandy
Harvard, Stephanie
Laroche, Marie-Laure
Mariette, Xavier
Saraux, Alain
Durand-Zaleski, Isabelle
Guillemin, Francis
Fautrel, Bruno

January 2014

International audienceOBJECTIVES: To estimate annual direct costs of early RA by resource component ...

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis : An evaluation of costs and effects

Krieckaert, C. L M
Nair, S. C.
Nurmohamed, M. T.
Van Dongen, C. J J
Lems, W. F.
Lafeber, F. P J G
Bijlsma, J. W J
Koffijberg, H.
Wolbink, G.
Welsing, P. M J

February 2015

Objective: To evaluate the cost-effectiveness of personalised treatment for rheumatoid arthritis (RA...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Etanercept.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of second-line biologic agent-Rituximab.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

Kuan-Chen Chen (5533430)
Chu-Hua Wu (5533433)
Chao-Hsiun Tang (4242457)
Kuo-Cherh Huang (748822)

July 2018

Differences in healthcare resource utilization and direct medical costs of patients with rheumato...

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.

Griffiths, RI
Bar-Din, M
MacLean, CH
Sullivan, EM
Herbert, RJ
Yelin, EH

August 2000

OBJECTIVE: To identify costs among rheumatoid arthritis (RA) patients receiving alternative disease-...

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.

Griffiths, RI
Bar-Din, M
MacLean, C
Sullivan, EM
Herbert, RJ
Yelin, EH

April 2001

We compared medical resource use and costs among rheumatoid arthritis (RA) patients receiving altern...

Economic consequences and potential benefits

Fautrel, Bruno
Verstappen, Suzanne M. M.
Boonen, Annelies

August 2011

Patients with established rheumatoid arthritis (RA) may incur important resource utilisation and wor...

Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis

Hyoungyoung Kim
Soo-Kyung Cho
Seongmi Choi
Seul Gi Im
Sun-Young Jung
Eun Jin Jang
Yoon-Kyoung Sung

June 2021

Objectives: To compare healthcare utilization and medical costs between patients with seronegative (...

Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada

Weijers L.
Baerwald C.
Mennini F. S.
Rodriguez-Heredia J. M.
Bergman M. J.
Choquette D.
Herrmann K. H.
Attina G.
Nappi C.
Merino S. J.
Patel C.
Mtibaa M.
Foo J.

January 2017

Rheumatoid arthritis (RA) is a chronic inflammatory disorder leading to disability and reduced quali...

Costs of treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs in rheumatic diseases – data from the Romanian Registry of Rheumatic Diseases

Catalin Codreanu
Claudiu C. Popescu
Bogdan Baleanu
Corina Mogosan

March 2020

Given the limited resources of the health system, rheumatologists are interested in reducing the cos...

Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis

Sangiorgi D
Benucci M
Nappi C
Perrone V
Buda S
Degli Esposti L

November 2015

Diego Sangiorgi,1 Maurizio Benucci,2 Carmela Nappi,3 Valentina Perrone,1 Stefano Buda,1 Luca Degli E...

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

Krieckaert, C.L.M.
Nair, S.C.
Nurmohamed, M.T.
Dongen, C.J.J. van
Lems, W.F.
Lafeber, F.P.J.G.
Bijlsma, J.W.J.
Koffijberg, H.
Wolbink, G.
Welsing, P.M.J.

January 2015

Objective To evaluate the cost-effectiveness of personalised treatment for rheumatoid arthritis (RA)...

Lapadula, G
Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428)

January 2012

Rheumatoid arthritis (RA) societal costs are high because the disease may cause not only restricted ...

1 Changing Pattern in the Prescription of Biological Treatment in Rheumatoid Arthritis. A 7- year Follow-up of 1839 Patients in Southern Sweden.

Maria K. Söderlin
Pierre Geborek
Maria K. Söderlin

August 2016

Objective. To study prescription patterns of biological treatment in rheumatoid arthritis (RA) patie...

Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort.

Chevreul, Karine
Haour, Georges
Lucier, Sandy
Harvard, Stephanie
Laroche, Marie-Laure
Mariette, Xavier
Saraux, Alain
Durand-Zaleski, Isabelle
Guillemin, Francis
Fautrel, Bruno

January 2014

International audienceOBJECTIVES: To estimate annual direct costs of early RA by resource component ...

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis : An evaluation of costs and effects

Krieckaert, C. L M
Nair, S. C.
Nurmohamed, M. T.
Van Dongen, C. J J
Lems, W. F.
Lafeber, F. P J G
Bijlsma, J. W J
Koffijberg, H.
Wolbink, G.
Welsing, P. M J

February 2015

Objective: To evaluate the cost-effectiveness of personalised treatment for rheumatoid arthritis (RA...

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Adalimumab.

Abstract

Extracted data

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of single biologic agent-Adalimumab.

Abstract

Extracted data

Related items

Related items